These proteins thus represent five biomarker candidates with the most promising diagnostic potential for identifying MIAC leading to HCA. The multidimensional exploratory analysis led to the detection of proteins down to a few nanograms per ml concentration as implied from the cathelicidin levels measured by ELISA in subsequent kinase inhibitor Dorsomorphin steps. Figure 1 Volcano plots constructed from iTRAQ quantification data. Verification of the exploratory results concerning amniotic fluid cathelicidin levels To verify our exploratory proteomic data we used ELISA to assess cathelicidin levels in both groups of the exploratory cohort (Fig. 2). Exploratory cohort patients with the presence of both MIAC and HCA had higher amniotic fluid cathelicidin levels than women without both MIAC and HCA (the presence of both MIAC and HCA: median 3.

6 ng/ml, IQR 2.0-102.2; with the absence of both MIAC and HCA: median 1.4 ng/ml, IQR 0.8�C2.4; p=0.0003). Figure 2 Verification of amniotic fluid cathelicidin levels. Validation Phase of the Study Demographic and clinical characteristics of the replication cohort An independent replication cohort was employed to further validate the verified findings regarding cathelicidin levels. To reach statistical power of 80% (��=0.01), the size of the replication cohort was calculated and required at least 38 women in each group. Table 2 presents the demographic and clinical characteristics of the women and newborns with respect to the presence and absence of MIAC and HCA. Women with MIAC and HCA had lower gestational age at sampling, lower gestational age at delivery, and lower birth weight.

Higher rates of MIAC, HCA, and funisitis were found in those with MIAC and HCA. All AV-951 women were self-reported as Caucasians. Table 2 Demographic and clinical characteristics of the women and newborns involved in the replication cohort. Validation of amniotic fluid cathelicidin in the replication cohort Women who had both MIAC and HCA had higher amniotic fluid cathelicidin levels than the rest of the women (the presence of both MIAC and HCA: median 3.1 ng/ml, IQR 17.0�C34.6; other women: median 1.4 ng/ml, IQR 1.0�C2.5; p<0.0001; Fig. 3). Figure 3 Validation of amniotic fluid cathelicidin levels on independent prospective replication cohort.